An interventional study of video polysomnography and Attention task in Aging and Alzheimer Disease, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 9 under way, 1 of them phase 3. Alzheimer Disease · Assistance Publique - Hôpitaux de Paris.
Among the 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris, this one is the 8th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 with no phase, and was the 24th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →9 of the 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50–80
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–90 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 65+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 50–90
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 55–85
By country, each count listing its studies:
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 91 across the 14 interventional studies, 97 across the 14 observational. Of the 19 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
4 of the studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05977712Assistance Publique - Hôpitaux de ParisCircadian Rhythm and Other Factors in Memory Clinic Patients | 2027-03 |
| NCT06501495Assistance Publique - Hôpitaux de ParisLinks Between Cognitive Deficits During Normal or Pathological Aging and Slow Waves Measured in EEG | 2027-04 |
| NCT06582199Assistance Publique - Hôpitaux de ParisPrecision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD | 2027-09 |
| NCT06068361Assistance Publique - Hôpitaux de ParisDiagnostic Evaluation of Dementia with Lewy Bodies Using a Multimodal Approach | 2027-09 |
Add all 4 to your calendar (.ics) → With an account.
Among the 28 studies in Alzheimer Disease by Assistance Publique - Hôpitaux de Paris, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
With age, memory processes (encoding, consolidation and retrieval) as well as daytime vigilance are altered. Sleep is also impaired in older adults, notably slow waves that are known to play a key role in memory consolidation. Interestingly, some slow waves can also be detected in EEG recordings during wakefulness, and have been related to vigilance fluctuations.
The investigators believe that slow waves, during both sleep and wakefulness, could constitute a common biomarker of sleep disturbances and daytime vigilance problems. A dysregulation of slow waves could thus explain the impact of aging on the different memory processes. Since alterations in memory capacity, attention, and sleep quality are further exacerbated in patients with Alzheimer's disease (AD), the investigators propose to study the links between aging (normal and pathological), sleep and daytime vigilance alterations, and their impacts on the different key stages of memory.
The investigators will examine the associations between slow waves and changes in memory and vigilance in normal and pathological aging by studying young adults, seniors without cognitive disorders, and patients with prodromal AD. By replaying sensory cues associated with learning material during sleep, the investigators will also evaluate the effectiveness of auditory stimulation during sleep to enhance memory consolidation in older adults without and without cognitive deficits.
Overall, this study aims to better understand the relationships between slow waves, aging, memory, and vigilance, providing insights into cognitive decline and potential interventions in aging and Alzheimer's disease.
Introduction Aging is accompanied by cognitive decline, particularly affecting memory functions. Additionally, both the quantity and quality of sleep decrease with advancing age, specifically altering sleep oscillations (such as slow waves) that are involved in the reactivation of memories and are thus central to memory consolidation.
Aging is also associated with difficulties in maintaining daytime vigilance, even after a period of rest, impacting cognitive function, including the encoding and retrieval of memories. Interestingly, recent studies have revealed the existence of sleep intrusions, in the form of slow waves, in wakefulness EEG recordings. These have been associated with subjective and objective markers of fatigue, predict transient lapses in attention, and are particularly present after sleep deprivation. the investigators believe that slow waves, during both sleep and wakefulness, could constitute a common biomarker of sleep disturbances and daytime vigilance problems. A dysregulation of slow waves (fewer during sleep, more during wakefulness) could thus explain the impact of aging on the three fundamental stages of the memory process (encoding, consolidation, and retrieval). Since alterations in memory capacity, attention, and sleep quality are further exacerbated in patients with Alzheimer's disease (AD), the investigators propose to study the links between aging (normal and pathological), sleep and daytime vigilance alterations, and their impacts on the different key stages of memory.
Aims Our main objective is to test the associations between slow waves (during sleep and wakefulness) and the alterations in memory and vigilance during normal and pathological aging by studying young adults, seniors without cognitive disorders, and patients of the same age with prodromal AD.
Additionally, the investigators aim to test the efficiency of targeted memory reactivation (TMR) in older adults with and without cognitive deficits. TMR is a technique that has been showed to boost memory consolidation in young adults and mice by replaying during sleep sensory cues that have been previously associated with the learning material.
Methods Participants To do so, the stydy will include three groups: young adults (18-35 y.o), older adults without cognitive deficits (65-80 y.o), and older adults of the same age and with cognitive deficits (patients with prodromal Alzheimer's disease). Prodromal stage of Alzheimer's disease diagnosis will be performed by trained neurologists at the at the Memory and Alzheimer's Disease Institute (IM2A) of the Pitié-Salpêtrière Hospital, according to international diagnostic criteria as a clinical phenotype of progressive amnestic syndrome of the hippocampal type, associated with biological markers of Alzheimer's disease from lumbar puncture (Aβ \< 600 pg/mL and ptau > 60 pg/mL). During their clinical follow-up at the IM2A, patients diagnosed with prodromal AD will be offered the opportunity to participate in the study, in agreement with their attending physician. Healthy volunteers (both young and elderly) will be recruited through public announcements via the Relay for Information on Cognitive Sciences (RISC), from patients' relatives, or through the Fondation Recherche Alzheimer. Participation of both patients and healthy individuals will be voluntary, free, and informed. Participants will be contacted (by phone or email) by one of the study investigators. They will be informed about the conduct and purpose of the research protocol.
Protocol All participants will spend 3 days in the Sleep Disorders Unit of the Salpêtrière Hospital, including two nights.
Day 1: Participants will arrive in the late afternoon and will be fitted with the sensors required for video-polysomnography to monitor vigilance and sleep stages throughout the experiment. Then, they will 1) complete an attention task (modified version of the Sustained Attention to Response Task, SART), 2) perform an associated memory task (old/new task) consisting on recognition of words they have seen in the SART task, and 3) their resting-state EEG activity will be recorded. They will sleep in the laboratory (night 1, without intervention).
Day 2: Participants will retake the word recognition task the morning after night 1. During the afternoon they will fill different sleep questionnaires to assess their subjective feeling about their sleep: Pittsburgh sleep quality index (PSQI), Epworth sleepiness scale and the REM Behavior Disorder Screening Questionnaire (RBDSQ), as well as the geriatric depression scale (GDS). In the late afternoon, they will perform the learning and test phases of the visuospatial memory task. They will then sleep in the laboratory (night 2, with TMR). During their slow-wave sleep, half of the sounds associated with the items from the visuospatial memory task will be replayed.
Day 3: Participants will once again perform the visuospatial memory test the morning after night 2.
Male or female Signed Affiliated with a social security system Native French speakers Completed at least 7 years of schooling (minimum 9th grade level)
Specific Inclusion Criteria for Each Group:
Patients:
Age: 60 to 85 years Prodromal stage of Alzheimer's disease diagnosed according to international diagnostic criteria, characterized by a clinical phenotype of progressive amnesic syndrome of the hippocampal type, associated with biological markers of Alzheimer's disease 1) from lumbar puncture (Aβ \< 600 pg/mL and ptau > 60 pg/mL)or 2) amyloid PET (positron emission tomography), or 3) with positive plasma Alzheimer's biomarkers
Cognitively Healthy Seniors:
Age: 60 to 85 years Age and sex matched with the Patients group "Cognitively healthy" status defined by a score of ≥ 26 on the (Mini-Mental State Examination), a score of ≥ 16 on the BREF (Batterie Rapide d'Efficience Frontale), and a score of ≥ 8 on the 5-word test
Young Adults:
Age: 18 to 35 years Sex matched with the Patients group "Cognitively healthy" status defined by a score of ≥ 26 on the MMSE (Mini-Mental State Examination), a score of ≥ 16 on the BREF (Batterie Rapide d'Efficience Frontale), and a score of ≥ 8 on the 5-word test
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
young adults, older adults without cognitive deficits, prodromal Alzheimer's Disease
Other: video polysomnography · Other: Attention task
video polysomnography during 2 nights
Attention task : SART Test (Sustained Attention to Response Task)
slow waves density
quantifying slow waves with their density (during sleep, wakefulness at rest and during tasks)
Time frame: 2 days
Started Apr 2025 (actual). Primary completion is estimated for Apr 2027, 24 months after the start.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 24 months is below that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →